The United States FDA has awarded Fast Track Designation to the investigational drug AVB-S6-500 for the potential treatment of platinum-resistant recurrent ovarian cancer. You can find out more detailed information…
According to a story from news-medical.net, a recent study suggests that a class of drugs called BRAF inhibitors could be an effective treatment option for ovarian cancer patients who carry…
According to a story from whtc.com, a recent study from the UK is calling into question the widely held belief that fertility treatments could increase the risk of ovarian cancer,…
A recent lawsuit against Johnson & Johnson claimed that the company’s talcum powder was responsible for cases of ovarian cancer. According to a July 13th report by NBC, a judge…
Clovis Oncology, Inc. has announced that they have submitted an application to the European Medicines Agency (EMA). The application is to extend the drug Rubraca’s®(rucaparib) marketing authorisation to include maintenance…
Results from a Phase 3 trial of the medicine Lynparza (olaparib) for the treatment of advanced ovarian cancer in women with the BRCA-mutation have been announced as positive. The full…
According to News Medical, a group of researchers at Johns Hopkins and the Bloomberg-Kimmel Institute for Cancer Immunotherapy recently found encouraging results for a study involving immunotherapy to treat a…
According to a story from PR Newswire, the drug development company AIVITA Biomedical recently announced that the first patient in its Phase II clinical trial has been randomized. This is…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
